A n A ly s i s
Metabolic interactions between multiple cell types are difficult to model using existing approaches. Here we present a workflow that integrates gene expression data, proteomics data and literature-based manual curation to model human metabolism within and between different types of cells. Transport reactions are used to account for the transfer of metabolites between models of different cell types via the interstitial fluid. We apply the method to create models of brain energy metabolism that recapitulate metabolic interactions between astrocytes and various neuron types relevant to Alzheimer's disease. Analysis of the models identifies genes and pathways that may explain observed experimental phenomena, including the differential effects of the disease on cell types and regions of the brain. Constraint-based modeling can thus contribute to the study and analysis of multicellular metabolic processes in the human tissue microenvironment and provide detailed mechanistic insight into high-throughput data analysis.
Constraint-based reconstruction and analysis of genome-scale microbial metabolic networks has matured over the past decade. This approach has a wide range of applications, such as providing insight into evolution, aiding in metabolic engineering, and providing a mechanistic bridge between genotypes and complex phenotypes 1, 2 . Computational methods 3 and detailed standard operating procedures 4 have been outlined for the reconstruction of high-quality prokaryotic metabolic networks, and many methods can be deployed for their analysis 5, 6 . Constraint-based modeling of metabolism entered a new phase with the publication of the human metabolic network (Recon 1) 7 , based on build 35 of the human genome. Methods allowing tissuespecific model construction have followed [8] [9] [10] .
Many tissue metabolic functions rely on interactions between cell types. Thus, methods are needed that integrate the metabolic activities of multiple cell types. Here, using Recon 1, we analyze and integrate ' omics data with information from detailed biochemical studies to build multicellular, constraint-based models of metabolism. We demonstrate this process by constructing and analyzing models of human brain energy metabolism, with an emphasis on central metabolism and mitochondrial function in astrocytes and neurons. Moreover, we provide three detailed examples, demonstrating the use of models to guide experimental work and provide biological insight into the metabolic mechanisms underlying physiological and pathophysiological states in the brain.
RESULTS
Building metabolic models of multiple cell types 'Omics data sets can be difficult to analyze owing to their size. However, such data sets can be used to construct large mechanistic models for specific tissues and cell types 8, 9 that serve as a context for further analysis. The workflow for generating multicellular models ( Fig. 1) consists of the following four steps.
Step 1. Reconstruct a metabolic network for the organism of interest from genome annotation, lists of biomolecular components and the literature 4 . Metabolic pathways and associated gene products are not completely known for any species. Thus, a reconstruction is refined through iterations of manual curation, hypothesis generation, experimental validation and incorporation of new knowledge. Recon 1 has been through five iterations 7 .
Step 2. Identify reactions specific to the tissue of interest. Many gene products are not expressed in all cells at any given time 11 . Therefore, the presence of a gene product, inferred from ' omics data, such as gene expression or mass spectrometry, is mapped to the metabolic network using associations linking genes to proteins and to reactions. This process may be performed manually or algorithmically 8,9 . Step 3. Partition the reconstruction, using manual curation of the literature, into compartments representing different cell types and organelles. The different cell types are linked with transport reactions, as supported by literature and experimental data. Initial context-specific reconstructions are incomplete and may contain false positives owing to contamination from proximal tissue. Moreover, few high-throughput data sets are cell-type specific. Thus, the initial reconstruction represents the union of metabolic networks from various cell types. After the reconstruction is partitioned using manual curation, it is converted into a model by specifying inputs, outputs and relevant parameters, and by representing the network mathematically 12 . Details of proper manual curation have been described 4 .
Step 4. Simulation and analysis 1, 2 . Once the network is accurately reconstructed and converted into an in silico model, it is used to A n A ly s i s generate hypotheses and to obtain insight into systems-level biological functions.
In contrast to previous approaches that reconstructed tissue-specific models 8-10 , the approach described here accounts for interactions between cell types within the tissue. First, published experimental results (e.g., immunohistochemistry staining of brain tissue 11 ) are used to refine the reconstructed network into individual cell type networks. Subsequently, interactions between these cell types are included as transporters that transfer metabolites between the different cell type models. This process results in a tissue-specific model that accounts for metabolic interactions between cells and the separation of metabolic functions into the relevant cell types. Thus they provide a more accurate view into tissue metabolism. Previous work had not taken these steps to generate multicellular tissue-specific models of this scale.
This workflow was used to build three different multicellular models of brain energy metabolism. Each model represents one canonical neuron type (that is, glutamatergic, γ-aminobutarate (GABA)ergic or cholinergic), its interactions with the surrounding astrocytes and the transport of metabolites through the blood-brain barrier (Fig. 2) . This reconstruction focuses on the core of cerebral energy metabolism, including central metabolism, mitochondrial metabolic pathways, and pathways relevant to anabolism and catabolism of the neurotransmitters glutamate, GABA and acetylcholine. Briefly, we began with the manually curated human metabolic reconstruction Recon 1 (ref. 7) (step 1). Next, we extracted relevant brain-specific reactions by mapping them to proteins expressed or localized to the brain as reported in the Human Protein Reference Database (release 5) 13 , H-inv (version 4.3) (HINV) 14 or The Human Proteome Organisation (HUPO) brain proteome project 15 ; additional reactions were added as dictated by biochemical data from the literature (step 2). Reactions and pathways were manually curated to verify their presence in the human brain, to determine celltype specificity and to add reactions unique to the different neuron types (step 3) (see Online Methods for complete details). Thus, the three models contain the high-flux pathways and important reactions in neuron and astrocyte metabolism. To our knowledge, these models currently represent the largest and most detailed models of brain energy metabolism [16] [17] [18] (Supplementary Notes) .
Our models of glutamatergic, GABAergic and cholinergic neurons contain 1,066, 1,067 and 1,070 compartment-specific interactions (that is, reactions, transformations and exchanges), respectively, involving 983, 983 and 987 compartment-specific metabolites. In total, the three models are associated with 403 genes. Lists of reactions, genes, citations and parameters used to constrain the models are detailed in Supplementary Tables 1-5. The validity of these models is demonstrated through comparisons to physiological data. Specifically, our models predict ATP production rates within 8% of the average published value, and internal flux measurements are consistent with experimentally measured values (Supplementary Notes). Moreover, three analyses using the models are detailed here (step 4). Most of these analyses cannot be done on previous brain models or on Recon 1 (ref. 7) as published. Thus, our models can provide novel insight into brain energy metabolism.
Identifying genes behind cell type-specific metabolic phenotypes
Alzheimer's disease is characterized by dementia and is diagnosed postmortem by histopathological features such as neurofibrillary tangles and β-amyloid plaques. Notably, metabolic rates of various brain regions decrease years before the onset of dementia 19 . Experiments have suggested that glutamatergic and cholinergic neurons are more affected in moderate stages of Alzheimer's disease 20 , whereas most GABAergic cells m/z
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Step Context-specific data GAD2 GAD1 Figure 1 A workflow for bridging the genotypephenotype gap with the use of high-throughput data and manual curation for the construction of multicellular models of metabolism. The models can be used to (i) predict disease-associated genes, such as glutamate decarboxylase;
(ii) analyze high-throughput data in the network context to identify sets of genes that change together and affect specific pathways, such as the brain-region-specific suppression of central metabolism in Alzheimer's disease patients;
(iii) analyze physiological data in the context of the model, thereby enabling, for example, the identification of tissue properties relevant to disease treatment, such as the calculation of the percentage of the brain that is cholinergic.
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Measured CMR of metabolites Figure 2 General structure of the models. Three models were built from the brain reconstruction. Each model consists of various compartments including the endothelium/blood, astrocytes, astrocytic mitochondria, neurons, neuronal mitochondria and an interstitial space between the cell types. Each neuron metabolic network was tailored to represent a specific neuron type, containing genes and reactions generally accepted to be unique to the neuron type. Mito, mitochondrion; Int, interstitial space; CMR, cerebral metabolic rate.
A n A ly s i s are relatively unaffected until later stages 21 . Genes responsible for these differences are not known. Thus, we first analyzed the models to identify genes that potentially underlie these cell type-specific effects. Analysis of our models yielded results consistent with known metabolic changes in Alzheimer's. Several central metabolic enzymes exhibit altered expression or activity in Alzheimer's disease, such as pyruvate dehydrogenase (PDHm), α-ketoglutarate dehydrogenase (AKGDm) and cytochrome c oxidase [22] [23] [24] . The activities of these enzymes are affected by the Alzheimer's disease-related proteins β-amyloid and Tau kinase 25, 26 . In silico, as the activities of PDHm and cytochrome c oxidase decrease, neurons demonstrate impaired metabolic capacity (Supplementary Notes and Fig. 1a ,b therein), and deficiencies in PDHm activity leads to a decreased cholinergic neurotransmission capacity (Supplementary Notes and Fig. 1c therein) .
The in vitro AKGDm activity shows the greatest impairment in brains from individuals with Alzheimer's disease examined postmortem (57% decrease compared to normal) 23 . An in silico analysis shows that this deficiency impairs the metabolic rate in glutamatergic and cholinergic neurons ( Fig. 3a) because it limits oxidative phosphorylation capacity in these neurons (Fig. 3b,c) . Such impairment of oxidative phosphorylation leads to neuronal apoptosis 27 . However, oxidative phosphorylation is not impaired in the GABAergic neuron model ( Fig. 3d) , consistent with the different phenotypes of GABAergic compared with glutamatergic and cholinergic neurons. Therefore, the models were further interrogated to identify a mechanism that allows GABAergic neurons to absorb the perturbation, thereby leading to the cell type-specific effects.
Simulations show that GABAergic neurons absorb the AKGDm perturbation through the GABA shunt ( Fig. 3e,f) , a pathway that uses 4-aminobutyrate transaminase and succinate-semialdehyde A n A ly s i s dehydrogenase to bypass part of the tricarboxylic acid (TCA) cycle. However, our models suggest that glutamatergic and cholinergic neurons cannot, despite carrying a small flux through the shunt enzymes ( Fig. 3e) . Support for these results includes recent evidence that suggests that cerebellar granule neurons, which have higher levels of GABA, can absorb perturbations to AKGDm through this shunt 28 .
To identify the mechanism allowing only GABAergic neurons to use the GABA shunt to absorb the AKGDm perturbation, an in silico analysis was performed to identify contributing genes. Briefly, each reaction was removed from the GABAergic model, followed by an assessment of the correlation of flux between AKGDm and oxidative phosphorylation (Supplementary Notes). This analysis suggested that the two isoforms of glutamate decarboxylase (GAD) could provide the cell type-specific neuroprotection.
GAD allows the GABA shunt to carry a higher flux following the AKGDm perturbation in GABAergic neurons; however, the lack of GAD in other neuron types greatly limits the use of the GABA shunt in silico (Fig. 3e) . Therefore, by fueling the GABA shunt, GAD may play a neuroprotective function, thus sparing of GABAergic systems in earlier Alzheimer's disease 21 .
Certain populations of glutamatergic and cholinergic cells tend to be lost earlier in Alzheimer's disease but others survive. Interestingly, although GAD is canonically encoded by a GABAergic gene, it occasionally shows low expression in other neuron types, including glutamatergic and cholinergic cells 29 . Therefore, such populations of non-GABAergic, GAD-expressing neurons would also be protected. Thus, we follow with an analysis of the correlation of GAD expression and Alzheimer's disease pathology for further validation.
If GAD has neuroprotective capacity in vivo, we would expect that brain regions with less GAD per neuron will be more affected in Alzheimer's disease, whereas regions with abundant GAD will be spared. To test this hypothesis, we used a compendium of published microarrays of neurons without tangles from six brain regions in Alzheimer's patients and age-matched, non-Alzheimer's controls 30 . In controls, GAD expression levels among the brain regions is consistent with the extent of neuron loss found in Alzheimer's disease patients; that is, brain regions with more neuron loss in Alzheimer's disease (e.g., the entorhinal cortex and hippocampus) have lower GAD expression in control patients, whereas relatively unaffected regions in Alzheimer's disease (e.g., superior frontal gyrus and visual cortex) show much higher levels of GAD expression ( Fig. 3g) .
In addition, if GAD is neuroprotective, neurons with low GAD expression should be lost in Alzheimer's disease, resulting in an increase in expression of GAD per neuron in histopathologically affected regions. In microarrays, we observed a significant increase in the expression of the brain-specific GAD2 in the entorhinal cortex and hippocampus in Alzheimer's disease (P = 0.0050 and 0.018, respectively; SAM test) ( Fig. 3h) . Expression of all other neuronspecific genes were tested as controls and showed no correlation with Alzheimer's disease pathology (Supplementary Notes and Fig. 2  therein) , except the genes encoding DLX2 and DLX5, which induce GAD expression in the brain ( Fig. 3h and Supplementary Notes and Fig. 3 therein) 31 . Therefore, these results lend additional support to the possibility that GAD is providing a neuroprotective effect and that this effect is correlated with the regional specificity of Alzheimer's disease. Moreover, the model was able to guide the identification of a gene and the mechanism for its role in Alzheimer's disease.
Pathway-based analysis of multicellular models Atrophy and the cell type-specific effects investigated above cannot fully explain the decreased metabolic rate in Alzheimer's disease in many brain regions 32 . Therefore, using the models as a context for analyzing gene expression data from Alzheimer's patients and age-matched controls, we searched for downregulated metabolic pathways within surviving cells in metabolically suppressed brain regions. This was done using PathWave 33 , a method that takes each model and maps microarray data to the metabolic pathways, which have been optimally arranged on a two-dimensional grid. Haar Wavelet transforms detected concerted regulation of neighboring enzymes in the models. Thus, we could identify groups of differentially expressed genes that are not solely related by annotation but that are connected by metabolic pathway functions, thereby providing a mechanistic view of the effects of differential gene expression (see Online Methods and Supplementary Notes) .
This analysis revealed that brain regions showed distinct changes in metabolic pathways (Supplementary Table 6 ). The visual cortex and superior frontal gyrus lack any differentially expressed pathways, consistent with previous work that shows little change in metabolic rate in Alzheimer's disease in these regions 30 . However, the posterior cingulate cortex (PC) and middle temporal gyrus (MTG) have the most significantly differentially expressed pathways (23 and 18, respectively). These two regions show significantly decreased metabolic rates in Alzheimer's disease but show fewer histopathological effects 30 . Both the entorhinal cortex and hippocampus also show decreases in expression of nine metabolic pathways, though the number may be lower since these regions suffer a high amount of neuron loss and only histopathologically healthy neurons were expression profiled. Therefore, more affected neurons may already have been lost or not profiled.
PathWave also revealed that the four brain regions showing substantially lower metabolic rates in Alzheimer's disease (PC, MTG, hippocampus and entorhinal cortex) 32 also show a significant suppression of glycolysis and the TCA cycle (P < 5 × 10 −4 ) ( Fig. 4) . In addition, the hippocampus, MTG and PC show a suppression of the malate-aspartate shuttle and oxidative phosphorylation. Individual regions also show a suppression of other pathways, such as heme biosynthesis (MTG, PC), ethanol metabolism (entorhinal cortex, PC) and several amino acid metabolism pathways. Thus, using pathway topology of our models as a context for microarray analysis, we find that the decreased metabolic rate in specific regions in Alzheimer's disease is associated with the downregulation of central metabolic gene expression in histopathologically normal neurons.
Identifying metabolic properties relevant to treatment Deficiencies in cholinergic neurotransmission have long been believed to contribute to Alzheimer's disease. Thus, treatment of Alzheimer's patients often includes efforts to enhance the cholinergic system. Although relevant to treatment, it is still not clearly understood which pathways are used to synthesize acetylcholine and what percentage of the brain participates in cholinergic neurotransmission.
Studies have demonstrated that cytosolic acetyl-CoA, which is used to synthesize the neurotransmitter acetylcholine, comes from the acetyl-CoA formed in the mitochondria. This tight coupling of acetylcholine to mitochondrial metabolism allows treatments that increase glucose uptake in the brain to improve cognitive functions in rats 34 and humans with severe cholinergic cognitive pathologies, such as Alzheimer's disease and trisomy 21 (ref. 35) . Pathways that transport acetyl-CoA carbon to the cytosol have been suggested; however, the mechanism is still not clear 36 .
Constraint-based modeling helped identify two pathways that could indirectly transport acetyl-CoA into the cytosol and provided insight into needed complementary pathways. To identify these pathways, reaction sets were identified by randomly removing reactions from Recon 1 until a minimum set was determined that couples the mitochondrial and cytosolic A n A ly s i s acetyl-CoA pools. This was repeated until more than 21,000 unique minimal reaction sets were identified. Singular value decomposition was then used to identify dominant sets of reactions that frequently co-occur.
The first singular vector is dominated by reactions that frequently co-occur in the reaction sets (e.g., water transport across cell membranes). However, the second and third singular vectors are dominated by reactions that usually co-occur or never co-occur ( Fig. 5) . These reactions cluster into three distinct pathways, providing hypotheses of pathways coupling acetylcholine synthesis and mitochondrial metabolism. After re-examining the literature and the 'omics data used in the reconstruction, we were able to eliminate the pathway using cytosolic acetyl-CoA synthetase ( Fig. 5a) and validate pathways using ATP-citrate lyase (ACITL) or cytosolic acetyl-CoA C-acetyltransferase (ACACT1r), which transport acetyl-CoA from the mitochondria to the cytosol on citrate or acetoacetate, respectively (Fig. 5b,c and Supplementary Notes) .
These two pathways were included in our cholinergic model, contributing to a correlation between the flux through mitochondrial pyruvate dehydrogenase and choline acetyltransferase (r = 0.45, P = 3 × 10 −247 ), consistent with the experimentally observed coupling between mitochondrial metabolism and acetylcholine production. ACITL and ACACT1r also correlate with choline acetyltransferase flux (P < 3 × 10 −90 ). Moreover, it has been reported that the inhibition of ACITL reduces the acetylcholine production rate by 30% 36 . 
A n A ly s i s
The in silico inhibition of ACITL reduces acetylcholine production by 7.3%. It is possible that the in silico decrease is smaller because the model can immediately adapt to the perturbation, whereas in vivo regulatory responses would take time to adapt. Notably, the in silico inhibition of ACACT1r reduces acetylcholine production by 39%. Thus, cholinergic neurotransmission depends on redundant pathways, and acetoacetate may play a more dominant role in transporting mitochondrial acetyl-CoA to the cytosol. Our analysis provides further insight into the coupling of mitochondrial metabolism to acetylcholine synthesis, which aids in the treatment of cholinergic disorders. However, knowledge of the abundance of cholinergic neurotransmission also aids in this purpose. It is difficult to identify cholinergic neurons, based solely on cell morphology, because cholinesterases and immunohistochemical markers for cholinergic neurons are also found in noncholinergic neurons and other tissues 37 . Therefore, it is unknown what percentage of all neurotransmission is cholinergic. Using our cholinergic model, we compute the percent contribution of cholinergic neurotransmission based on published data 38 . The data were obtained from rat brain minces, incubated in solutions containing [1-14 C]pyruvate or [2-14 C]pyruvate. Both acetylcholine and radiolabeled CO 2 were measured at various titrations of several pyruvate dehydrogenase inhibitors.
The cholinergic model was subjected to similar levels of pyruvate dehydrogenase inhibition. The simulations successfully reproduced the experimental linear relationship between acetylcholine production and metabolic rate, and acetylcholine production was correlated with CO 2 release (r = 0.68).
The fraction of cholinergic neurotransmission for the brain was computed by randomly choosing points from both the distributions of experimental data and distributions predicted by the simulations. A scaling factor was subsequently found that reconciles the two. This was repeated for 14 different combinations of pyruvate labeling and pyruvate dehydrogenase inhibitors 38 , yielding a median predicted cholinergic portion of total brain neurotransmission of 3.3% (Fig. 6a) . After adding this new parameter to the model, the predictions correspond well with experimental data sets (Fig. 6b) , including data representing three pyruvate dehydrogenase inhibitors withheld from the previous computations (Fig. 6c,d) . Thus, the model was used in conjunction with experimental data to gain insight into physiological observations and derive physiological parameters, which are dependent on systems-level activity and are relevant to treatment.
DISCUSSION
In this study we presented a workflow for generating tissue-specific, multicellular metabolic models. Through the analysis and integration of ' omics data, followed by manual curation, we used this workflow to build a first-draft, manually curated, multicellular, metabolic reconstruction of brain energy metabolism. Three models were generated from this reconstruction, representing different types of neurons coupled to astrocytes. We used these models in three distinct analyses, in which we made predictions and gained systems-level insights into Alzheimer's disease and cholinergic neurotransmission.
As experimental methods and data resolution improve, the accuracy of these models and their predictions should also improve. Improvements in neuroimaging and metabolomics will allow for more precise quantification of metabolite flow through the bloodbrain barrier, which is of interest because dysfunction of this system accompanies many neurological disorders and injuries 39 . In addition, improvements in transcriptomics and proteomics will provide higherresolution quantification of cell-and organelle-specific genes and proteins. These data will allow models to account for neuron groups in specific brain regions, subcellular heterogeneity within cells and the inclusion of less abundant glial cells. For example, higher-resolution models may provide insight into metabolic changes in specific cell populations, such as the structures closely related to the olfactory system, which are affected early on in Alzheimer's disease 40 .
Insight into mammalian tissue-specific metabolism may be gained as more multicellular models are constructed. Our models demonstrate metabolic coupling and synergistic activities that more coarse-grained models miss, as the three analyses presented here were not possible using Recon 1 or the previous brain metabolism models. The compartmentalization of metabolic processes within cells 41 , between cells 42 and in host-pathogen interactions 43 has an important role in normal physiology. Therefore, such models may provide greater insight and more accurately predict both true cellular functions and responses to medical interventions 44 . This insight will be attained as many analytical methods, in addition to those demonstrated in this work, will be CO 2 release (µmol * g wet brain −1 * min −1 ) 14 CO 2 release (µmol * g wet brain −1 * min −1 ) 14 CO 2 release (µmol * g wet brain −1 * min −1 )
Exp. data Figure 6 Model-aided prediction of cholinergic contribution is consistent with experimental acetylcholine production. Percent brain cholinergic neurotransmission was predicted based on 14 sets of experimental data in which brain minces were fed [1-14 C]-pyruvate or [2-14 C]-pyruvate, followed by measurement of 14 C-labeled CO 2 and acetylcholine. (a) For each experiment, the feasible amount of the brain that can generate the experimental response was computed, centering at 3.3%. (b) This parameter was used in the analysis, and the updated model predictions were consistent with experimental data, such as seen in the case of treating the brain minces with [1-14 C]-pyruvate and increasing levels of the pyruvate-dehydrogenase inhibitor bromopyruvate. (c,d) Moreover, the updated model predictions were consistent with measured 14 C-labeled CO 2 and acetylcholine production for brain minces that were treated with three PDHm inhibitors withheld from previous computations for both supplementation with A n A ly s i s developed and deployed in multicellular reconstructions ranging from constraint-based analyses 5 to topological studies 45 .
This study serves as an example of how mechanistic relationships between genotype and phenotype can be built through the difficult task of multi-omic data integration 46 . From the genotype one can begin to reconstruct the network for an organism. The integration of high-throughput data and careful manual curation can add context-specific mechanistic network structure to genomics information. Thus, this network becomes a representation of complex genetic interactions and biochemical mechanisms underlying observed phenotypes. This complex, but mechanistic, relationship between the genotype and phenotype can be used as a foundational structure upon which additional high-throughput data can be analyzed and predictive simulations can be conducted, thus leading to improved understanding, testable hypotheses and increased knowledge 1, 2, 44 .
METHODS
Methods and any associated references are available in the online version of the paper at http://www.nature.com/naturebiotechnology/.
Note: Supplementary information is available on the Nature Biotechnology website.
ONLINE METHODS
Reconstruction of iNL403. This work focuses on the core of cerebral energy metabolism and the pathways that play a critical role in cell type-specific functions in the brain. The pathways in this work include mitochondrial metabolic pathways, central metabolic pathways closely tied to mitochondrial function and additional pathways that are needed for modeling neuron and astrocyte functions. To reconstruct these pathways, a list of known human mitochondrial, glycolytic and transport reactions were extracted from the manually curated human metabolic reconstruction Recon 1 (ref. 7) . From this list, reactions were directly added to the brain reconstruction if brainlocalized protein or gene expression was suggested by the Human Protein Reference Database (release 5) 13 or HINV 14 , both of which provide tissue expression presence calls for each gene. Proteomics data from live human brain, acquired for the HUPO brain proteome project 15 , were also used (see Supplementary Table 7 for accession numbers). Additional reactions were added as dictated by biochemical data from the literature ( Supplementary  Table 1 ). This reconstruction is designated iNL403 because it contains 403 genes. Reactions and pathways were manually curated to verify their presence in the human brain and to determine cell-type localization, thus yielding a first-draft metabolic reconstruction of the brain metabolic network. Reactions unique to the different neuron types were determined from the literature (see notes in Supplementary Table 1) , and consist largely of the reactions needed to make and metabolize their associated neurotransmitters. A list of all reactions, supporting data, citations and a comparison with previous brain metabolism models can be found in Supplementary Tables 1-4 and 8. Three SBML models representing the union of reactions from the neuron-type specific models can be found as Supplementary Models 1-3 . Neuron-type specific models in SBML format and model updates can be obtained from http://systemsbiology.ucsd.edu/In_Silico_Organisms/Brain.
Constraint-based modeling.
Constraint-based modeling and analysis of metabolic networks have been previously described 5, 12 . Briefly, all of the reactions are described mathematically by a stoichiometric matrix, S, of size m × n, where m is the number of metabolites and n is the number of reactions, and each element is the stoichiometric coefficient of the metabolite in the corresponding reaction. The mass balance equations at steady state are represented as
where v is the flux vector 12 . Maximum and minimum fluxes and reaction reversibility, when known, are placed on each reaction, further constraining the system as follows
At this point the model can then be used with many constraint-based methods 5 to study network characteristics.
The S matrix was constructed with the mass and charge balanced reactions from the reconstruction. Select metabolites, known to cross the blood-brain barrier, were added as exchange reactions, allowing those metabolites to leave or enter the extracellular space in the model. A few metabolites from network gaps were allowed to enter or leave the system from the cytosol or mitochondria. This was only done when transporter mechanisms or subsequent pathway steps were not known, and when their entrance or removal from the system was necessary for model function. When available, cerebral metabolic rates were used from published data to constrain the upper and lower bounds of the exchange reactions 45, 46 . All parameters are detailed in Supplementary Tables 1 and 5. Parameters derived from rat data were varied to demonstrate that results presented here were robust and therefore relevant to human metabolism, and constraint-based methods were further employed to assess and compare the model to metabolic functions of the brain (Supplementary Notes) .
Monte Carlo sampling. Monte Carlo sampling was used to generate a set of feasible flux distributions (points). The method is based on the artificially centered hit-and-run algorithm with slight modifications. Initially, a set of nonuniform pseudo-random points, called warm-up points, is generated. In a (1) (1)
series of iterations, each point is randomly moved, always remaining within the feasible flux space. This is done by (i) choosing a random direction, (ii) computing the limits of how far one can travel in that direction and (iii) choosing a new random point along this line. After many iterations, the set of points is mixed and approaches a uniform sample of the solution space, thus providing a distribution for each reaction that represents the range and probability of the flux for each reaction, given the network topology and model constraints. For more detail, see the Supplementary Notes.
Simulating enzyme deficiencies. Enzyme deficiencies were obtained from the literature 23 . To simulate each deficiency, the distribution for all candidate flux states was determined using Monte Carlo sampling. From this distribution, the most probable flux was found and the reaction upper bound was reduced by the fraction reported in the literature. All candidate states were then recomputed and compared with normal candidate flux states.
Alzheimer's disease microarray analysis. Microarrays were obtained from the Gene Expression Omnibus (GSE5281). Arrays consist of 161 Affymetrix Human Genome U133 Plus 2.0 Arrays that profile the gene expression from laser-capture, microdissected, histopathologically normal neurons from six different brain regions of Alzheimer's disease patients and age-matched controls. These arrays were not used in model construction.
Arrays were normalized using the GC Robust Multi-array Average (gcrma) normalization function in the bioconductor package for R. Pearson's correlation coefficients were computed for all array pairs, and arrays with r < 0.8 were discarded (that is, GSM119643, GSM119661, GSM119666 and GSM119676).
Different arrays had different levels of glial contamination. Therefore, to assess the amount of GAD (neuron-specific), the GAD1 and GAD2 levels on each array were normalized as follows. For each array, the relative amount of neuron material was determined by computing a ratio for four neuron-specific genes to the median level across all arrays. Neuron-specific genes were chosen to represent different neuron parts, including the soma, axon and synaptic bouton for each neuron marker gene g i . Because GAD genes are neuron specific in the central nervous system, these were normalized for each array by the associated relative amount of neuron material, thus termed GAD NMN for neuron-marker normalized GAD. It is assumed in this study that the four neuron marker transcripts used here do not change their expression level between Alzheimer's patients and age-matched controls, in the cell populations sampled for microarray analysis. This assumption is made since there are no published studies that demonstrate that these genes change expression in healthy cells through the progression of Alzheimer's disease and because efforts were made to only expression profile histopathologically normal neurons. It is possible that there is downregulation of some neuron marker transcripts among neurons bearing neurofibrillary tangles, as synapse loss is a hallmark of Alzheimer's disease 20 . However, the arrays used in this study profile histopathologically normal neurons and the surrounding glial cells. Therefore, it is not expected that there will be significant changes in the expression of these key neuronal genes in the data used here. Lastly, the inclusion of multiple genes from different cell regions aims to minimize the effects from expression changes not attributable to glial cell contamination. The results presented in this work are robust to the removal of each neuron marker gene (Supplementary Notes and Fig. 4 therein) .
PathWave analysis. PathWave allows for the elucidation of pathways that significantly change together. Its advantage over other methods, such as Gene Set Enrichment Analysis, is that it takes metabolic network connectivity into account to identify changes in pathways, thereby identifying significantly differentially regulated pathways in which the gene products are mechanistically connected.
PathWave was used as published previously 33 . The reactions in each model were subdivided into biologically relevant functional pathways. Reactions that 
